Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics source : Www.rubiustx.com save search
Induction of Antigen-Specific Immune Tolerance in Type 1 Diabetes by Antigen-Expressing Red Cell Therapeutics
Published: 2022-06-22 (Crawled : 12:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -11.73%
H: 21.91%
C: 14.92%
therapeutics diabetes
A Phase 1/2 Study of RTX-224, an Engineered Red Blood Cell Expressing 4-1BB Ligand and Membrane-Bound IL-12, for the Treatment of Patients with Select Advanced Solid Tumors
Published: 2022-05-26 (Crawled : 21:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 1.89%
H: 10.19%
C: 10.19%
rtx-224 treatment blood phase 1
Phase 1 Trial of RTX-240, Allogeneic Red Blood Cells Engineered to Express 4-1BBL and Trans-Presented IL-15, in Patients with Advanced Solid Tumors
Published: 2022-04-08 (Crawled : 17:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 1.19%
H: 2.28%
C: -46.21%
rtx-240 blood trial phase 1
RTX-224, An Engineered Allogeneic Red Cell Therapeutic Expressing 4-1BBL and IL-12, Activates Immune Cells in Blood and Spleen to Promote Tumor Growth Inhibition in Mice
Published: 2021-11-12 (Crawled : 12:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 2.27%
H: 0.0%
C: 0.0%
blood growth
Anti-Tumor Effects of RTX-240: an Engineered Red Blood Cell Expressing 4-1BB Ligand and Interleukin-15
Published: 2021-07-13 (Crawled : 16:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -0.67%
H: 1.84%
C: -0.84%
blood
A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers
Published: 2021-06-04 (Crawled : 13:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.62%
H: 3.05%
C: 1.94%
treatment blood phase 1 positive rtx-321 cancer phase 3
Engineered Red Blood Cells as an Off-the-Shelf Allogeneic Anti-Tumor Therapeutic
Published: 2021-05-12 (Crawled : 12:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -1.66%
H: 2.39%
C: -6.29%
blood
A Phase 1 Trial of RTX-240, an Allogeneic Engineered Red Blood Cell With Cell-Surface Expression of 4-1BBL and Trans-Presented IL-15, in Patients With Advanced Solid Tumors
Published: 2021-04-10 (Crawled : 00:20) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
| Email alert
Add to watchlist
blood solid tumors phase 1 trial phase 3 phase 2
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PALI | $6.57 57.93% 19M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
PRSO | $1.79 40.95% 38M
|
Manufacturing
MCBC | $13.795 38.92% 820K
|
Finance
BTTR | $6.86 34.51% 5.2M
|
Manufacturing
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.